Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study
Discover Oncology · 09.03.2024 · 15 (1)
DOI: 10.1007/s12672-024-00917-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 09.03.2024. Verfasst von Guosheng Yuan und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, N…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, the Postdoctoral Research Foundation of China.
Abstract (Originalsprache)
Objectives
To explore the efficacy and safety of Transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC).
Methods
456 patients with HCC receiving either TACE in combination with ICIs and TKIs (combination group, n = 139) or TACE monotherapy (monotherapy group, n = 317) were included from Apr 2016 to Dec 2021 in this retrospective study. We employed propensity score matching (PSM), performed 1:2 optimal pair matching, to balance potential bias.
Results
The mean follow-up time is 24.7 months (95% CI 22.6–26.8) for matched patients as of March 2022. After matching, the combination group achieved longer OS and PFS (median OS:21.9 vs. 16.3 months, P = 0.022; median PFS: 8.3 vs. 5.1 months, P < 0.0001) than TACE monotherapy group. The combination group had better objective response rate (ORR) and disease control rate (DCR) (ORR: 52.5% vs. 32.8%, P < 0.001; DCR: 82.7% vs. 59.6%, P < 0.001). Subgroup analysis showed that patients who received “TKIs + ICIs” after the first TACE procedure (after TACE group) achieved longer OS than those before the first TACE procedure (before TACE group) (26.8 vs. 19.2 months, P = 0.011). Adverse events were consistent with previous studies of TACE-related trials.
Conclusions
TACE plus TKIs and ICIs appeared to deliver longer PFS and OS in HCC patients than TACE monotherapy. “TKIs + ICIs” co-treatment within 3 months after the first TACE procedure might be a better medication strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 51…
- Department of Oncology, Shunde Hospital, Southern Medical University, Shunde, Guangdong, 528300, People's Republic of China.
- Department of Medical Oncology, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, 310003, People's Republic of China.
- Division of Vascular and Interventional Radiology, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, People's Republic of China. nfyyphj@163.com.
Förderung
- the National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- the Postdoctoral Research Foundation of China
Zitieren
APA
Yuan, G., Li, W., Zang, M., Li, R., Li, Q., Hu, X., Zhang, Q., Huang, W., Ruan, J., Pang, H., & Chen, J. (2024). Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-00917-1
Vancouver
Yuan G, Li W, Zang M, Li R, Li Q, Hu X, et al. Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-00917-1
BibTeX
@article{Yuan2024,
author = {Yuan, Guosheng and Li, Wenli and Zang, Mengya and Li, Rong and Li, Qi and Hu, Xiaoyun and Zhang, Qi and Huang, Wei and Ruan, Jian and Pang, Huajin and Chen, Jinzhang},
title = {Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study},
journal = {Discover Oncology},
year = {2024},
volume = {15},
number = {1},
doi = {10.1007/s12672-024-00917-1}
}
EUVIMED